RVTY Quote, Financials, Valuation and Earnings

Avantor, Inc. has a net margin of 6.76% compared to Revvity, Inc.'s net margin of -43.84%. Revvity, Inc.'s return on equity of 3.05% beat Avantor, Inc.'s return on equity of -1.4%.

Revvity, Inc. has a consensus price target of $114.38, signalling upside risk potential of 18.18%. On the other hand Avantor, Inc. has an analysts' consensus of $13.32 which suggests that it could grow by 18.2%. Given that Avantor, Inc. has higher upside potential than Revvity, Inc., analysts believe Avantor, Inc. is more attractive than Revvity, Inc..

Revvity, Inc. has a beta of 1.059, which suggesting that the stock is 5.937% more volatile than S&P 500. In comparison Avantor, Inc. has a beta of 0.930, suggesting its less volatile than the S&P 500 by 7.02%.

Revvity, Inc. has a quarterly dividend of $0.07 per share corresponding to a yield of 0.29%. Avantor, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revvity, Inc. pays 11.63% of its earnings as a dividend. Avantor, Inc. pays out -- of its earnings as a dividend. Revvity, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity, Inc. quarterly revenues are $698.9M, which are smaller than Avantor, Inc. quarterly revenues of $1.6B. Revvity, Inc.'s net income of $47.2M is higher than Avantor, Inc.'s net income of -$711.8M. Notably, Revvity, Inc.'s price-to-earnings ratio is 48.40x while Avantor, Inc.'s PE ratio is 10.97x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity, Inc. is 4.09x versus 1.17x for Avantor, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Azenta, Inc. has a net margin of 6.76% compared to Revvity, Inc.'s net margin of 32.45%. Revvity, Inc.'s return on equity of 3.05% beat Azenta, Inc.'s return on equity of 1.44%.

Revvity, Inc. has a consensus price target of $114.38, signalling upside risk potential of 18.18%. On the other hand Azenta, Inc. has an analysts' consensus of $40.17 which suggests that it could grow by 15.75%. Given that Revvity, Inc. has higher upside potential than Azenta, Inc., analysts believe Revvity, Inc. is more attractive than Azenta, Inc..

Revvity, Inc. has a beta of 1.059, which suggesting that the stock is 5.937% more volatile than S&P 500. In comparison Azenta, Inc. has a beta of 1.288, suggesting its more volatile than the S&P 500 by 28.831%.

Revvity, Inc. has a quarterly dividend of $0.07 per share corresponding to a yield of 0.29%. Azenta, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revvity, Inc. pays 11.63% of its earnings as a dividend. Azenta, Inc. pays out -- of its earnings as a dividend. Revvity, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity, Inc. quarterly revenues are $698.9M, which are larger than Azenta, Inc. quarterly revenues of $159.2M. Revvity, Inc.'s net income of $47.2M is lower than Azenta, Inc.'s net income of $51.7M. Notably, Revvity, Inc.'s price-to-earnings ratio is 48.40x while Azenta, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity, Inc. is 4.09x versus 2.67x for Azenta, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Bruker Corp. has a net margin of 6.76% compared to Revvity, Inc.'s net margin of -6.8%. Revvity, Inc.'s return on equity of 3.05% beat Bruker Corp.'s return on equity of -1.2%.

Revvity, Inc. has a consensus price target of $114.38, signalling upside risk potential of 18.18%. On the other hand Bruker Corp. has an analysts' consensus of $51.79 which suggests that it could grow by 7.84%. Given that Revvity, Inc. has higher upside potential than Bruker Corp., analysts believe Revvity, Inc. is more attractive than Bruker Corp..

Revvity, Inc. has a beta of 1.059, which suggesting that the stock is 5.937% more volatile than S&P 500. In comparison Bruker Corp. has a beta of 1.174, suggesting its more volatile than the S&P 500 by 17.405%.

Revvity, Inc. has a quarterly dividend of $0.07 per share corresponding to a yield of 0.29%. Bruker Corp. offers a yield of 0.42% to investors and pays a quarterly dividend of $0.05 per share. Revvity, Inc. pays 11.63% of its earnings as a dividend. Bruker Corp. pays out 26.44% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity, Inc. quarterly revenues are $698.9M, which are smaller than Bruker Corp. quarterly revenues of $860.5M. Revvity, Inc.'s net income of $47.2M is higher than Bruker Corp.'s net income of -$58.5M. Notably, Revvity, Inc.'s price-to-earnings ratio is 48.40x while Bruker Corp.'s PE ratio is 77.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity, Inc. is 4.09x versus 2.13x for Bruker Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience, Inc. has a net margin of 6.76% compared to Revvity, Inc.'s net margin of -5.98%. Revvity, Inc.'s return on equity of 3.05% beat Harvard Bioscience, Inc.'s return on equity of -155.33%.

Revvity, Inc. has a consensus price target of $114.38, signalling upside risk potential of 18.18%. On the other hand Harvard Bioscience, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 175.71%. Given that Harvard Bioscience, Inc. has higher upside potential than Revvity, Inc., analysts believe Harvard Bioscience, Inc. is more attractive than Revvity, Inc..

Revvity, Inc. has a beta of 1.059, which suggesting that the stock is 5.937% more volatile than S&P 500. In comparison Harvard Bioscience, Inc. has a beta of 1.531, suggesting its more volatile than the S&P 500 by 53.123%.

Revvity, Inc. has a quarterly dividend of $0.07 per share corresponding to a yield of 0.29%. Harvard Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Revvity, Inc. pays 11.63% of its earnings as a dividend. Harvard Bioscience, Inc. pays out -- of its earnings as a dividend. Revvity, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Revvity, Inc. quarterly revenues are $698.9M, which are larger than Harvard Bioscience, Inc. quarterly revenues of $20.6M. Revvity, Inc.'s net income of $47.2M is higher than Harvard Bioscience, Inc.'s net income of -$1.2M. Notably, Revvity, Inc.'s price-to-earnings ratio is 48.40x while Harvard Bioscience, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Revvity, Inc. is 4.09x versus 0.37x for Harvard Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.